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EGFR-TKI
Interstitial lung disease (ILD) is an uncommon toxicity reported with 
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKI). Japanese patients (perhaps East Asians) appear to have a higher 
risk (1.6-3.5%) than patients in the rest of the world (9,10). The clinical 
presentation may be acute and dramatic and the radiographic ﬁnd-
ings resemble ARDS. Treatment is supportive and corticosteroids may 
beneﬁt. The mortality is high at one-third to one-half of all patients 
who develop ILD. An expert panel reviewed treatment related fatal ILD 
in the TRIBUTE trial where patients were randomized to chemotherapy 
plus erlotinib or placebo (11). There were 3 fatal ILD (3 of 526) (0.6%) 
attributed to erlotinib. One was biopsy conﬁrmed ILD showed BOOP 
histologically. All 3 cases had typical clinical presentation of acute 
or subacute onset of dyspnea with rapid progression to respiratory 
failure. Lung biopsies from other reports of ILD due to FGFR-TKI 
have reported diffuse alveolar damage. Japanese investigators identi-
ﬁed 70 cases of ILD, of which 31 died due to geﬁtinib for a prevalence 
rate of 3.6% and mortality of 1.6%. ILD was associated with male sex 
(OR=3.1), history of smoking (OR=4.79) and coincidence interstitial 
pneumonia (OR = 2.89) (12). 
Antiangiogenic Agents
These agents are a new class of drugs that are associated with a distant 
array of toxicities such as hemorrhage, hypertension, thromboem-
bolic events and proteinuria. In a randomized phase II trial of ECOG, 
Johnson et al treated patients with paclitaxel, carboplatin and bevaci-
zumab at 2 different doses (13). Six patients experienced a major life 
threatening bleed described as hemoptysis or hematemesis. Four events 
were fatal. All six had centrally located tumors close to major blood 
vessels. Five had cavitation or necrosis of tumors. Four of the severe 
hemorrhages were in squamous cell cancers. In the phase III ECOG 
trial, patients with hemoptysis, deep venous thrombosis, anticoagulant 
therapy or squamous cell histology were excluded. Grade 3 or greater 
bleeding events occurred in 4.4% of patients on the bevacizumab 
arm versus 0.7% (19 patients vs 3) on the chemotherapy only arm. 
Fatal hemoptysis occurred in 5 patients receiving chemotherapy plus 
bevacizumab (none on chemo only treatment). Phase II trials reported 
at ASCO in 2006 using the small molecule VEGF inhibitors, sunitinib 
and soraﬁnib, have also observed cases of radiographic tumor cavita-
tion and/or massive or fatal hemoptysis. This hemorrhagic toxicity is 
thought to be a class effect of the antiangiogenic agents.
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Lung cancer is a major cause of cancer-related deaths world-wide with 
non-small cell lung cancers (NSCLC) representing the majority of 
these cancers. There has been signiﬁcant interest in the utilization of 
more comprehensive technologies that deﬁne the molecular alterations 
associated with lung cancer and in particular lung adenocarcinoma and 
squamous cell carcinomas as they represent the most common histo-
logical subtypes. Genomic approaches that examine DNA copy number 
variation such as comparative genomic hybridization (CGH), array 
CGH and single nucleotide polymorphism (SNP) arrays have now been 
applied to lung cancer and have been used to deﬁne the most frequently 
observed regions of loss and gain, as well as intra-chromosomal DNA 
ampliﬁcation events. This has helped deﬁne potential tumor suppressor 
genes and oncogenes in these regions of loss and gain/ampliﬁcation 
respectively that are common to lung cancer as well as those more fre-
quently observed in speciﬁc histological subtypes. The results from the 
last decade of work utilizing these tools will be summarized. Current 
studies are now focusing on these speciﬁc regions to deﬁne the critical 
genes that are likely selected for and play an important role in lung cell 
malignant transformation and/or tumor progression. 
Genomic-based analyses also includes the use of more global, gene 
expression proﬁling of lung tumor mRNA. These studies have been 
used to identify genes that deﬁne, or are primarily associated with 
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a speciﬁc cancer histological subtype, that may be predictive of the 
clinical outcome of a patient, that are associated with the response 
to a particular therapeutic modality, or that provide insight into the 
general processes that are associated with the malignant phenotype. In 
most instances patients with surgically resectable lung cancer (stages 
I to III) have been utilized for these studies and data will be presented 
indicating that gene expression proﬁles can aid in identifying patients 
with early stage disease who currently receive only surgery that may 
also beneﬁt from adjuvant therapy. The proper design of these studies 
including the use of training and test sets of samples, validation of 
array data using alternate technologies such as real-time RT-PCR, and 
the validation of identiﬁed proﬁles or predictors using independent test 
sets will be discussed. Selected examples of large gene proﬁling studies 
will be presented including results from our group that examined 129 
squamous cell lung carcinomas (Raponi et al, Cancer Research, 2006) 
and a multi-institutional collaborative analysis that has recently proﬁled 
500 lung adenocarcinomas using oligonucleotide arrays. 
The proteomic analysis of lung cancers have to date utilized a wide 
variety of technologies and is a rapidly evolving area of investigation. 
Global analyses of lung cancer have included the use of two-dimen-
sional gel electrophoresis (2D-PAGE) for separation of tumor proteins 
with protein identiﬁcation using matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS), as well as the use of the 
alternate technology of surface-enhanced laser desorption ionization 
mass spectrometry (SELDI-MS). Each tool has speciﬁc advantages and 
disadvantages which will be discussed. Speciﬁc subsets of proteins of 
interest in tumors such as cell signaling molecules and their activa-
tion state have and are being examined using antibody-based protein 
arrays as well as using tissue microarrays (TMAs) composed of large 
numbers of cores of parafﬁn-embedded lung cancers. TMAs have 
become a highly utilized tool that allows for not only validation of 
candidates identiﬁed with gene or protein proﬁling tools but also al-
lows for combined genomic-based analyses including ﬂuorescence in 
situ hybridization (FISH) to potentially identify the basis for candi-
date protein over-expression such as gene ampliﬁcation or deletion. 
Because of the disadvantages of current technologies investigators have 
begun utilizing liquid two dimensional-based methods for the separa-
tion of proteins from primary tissues such as lung cancers or cells. 
One technology incorporates the use of isobaric tagging (iTRAQ) of 
proteins and the 2D-liquid chromatography separation of proteins and 
fragments followed by tandem mass spectrometry of the tagged, pooled 
peptides. This has been recently used to deﬁne differentially expressed 
proteins associated with the epithelial-mesenchymal transition in lung 
cancer (Keshamouni et al, J Prot Res, 2006). Additional methods utilize 
liquid phase separation of proteins with chromatofocusing in the ﬁrst 
dimension and nonporous reverse phase (NPS-RP) HPLC in the second 
dimension, followed by ESI-TOF mass spectrometry to identify proteins 
differentially expressed. Advances in these tools will allow more de-
tailed analyses of the lung cancer proteome as the labor-intensive early 
technologies represent a serious disadvantage that limited their use. 
Additional proteomic technologies that have potential to aid in the early 
detection of lung cancer are approaches include the serological analysis 
of recombinant cDNA expression libraries of human tumors with 
autologous serum or (SEREX). SEREX has been used to demonstrate 
that the humoral immune response of cancer patients can be used to 
identify novel tumor antigens. Because of the SEREX approach is not 
conducive to the study of sera from hundreds of patients we developed 
a high-density phage-epitope microarray derived from the biopanning 
of a lung cancer phage display library (Chen et al, Cancer Research, 
2007). Similar approaches have been described by Zhong et al, Am 
J Resp Crit Care Med, 2005. Using a 2,304 element phage-epitope 
microarray, we interrogated a total of 250 sera from cancer patients and 
controls to develop an “autoantibody proﬁle” of lung adenocarcinoma. 
The phage-epitope microarray strategy facilitated easy identiﬁca-
tion of humoral response targets by phage-epitope cDNA sequencing 
and individual candidates including ubiquilin 1 were identiﬁed. This 
candidate was validated on an independent set of serum samples from 
another institution and suggested that autoantibodies may provide one 
additional proteomic-based method that is noninvasive and may have 
potential for early lung cancer detection. 
Genomic and proteomic strategies are rapidly evolving but will likely 
continue to improve upon our ability to more comprehensively and 
sensitively interrogate gene alterations and identify more speciﬁc can-
didate biomarkers in lung cancer. This will hopefully lead to improved 
patient survival by allowing early detection and effective targeting of 
the critical cellular pathways needed by lung cancer cells to survive and 
spread.
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Introduction
Bronchoscopy dates back to the early 19th century where rigid illumi-
nating tubes were used to examine the tracheobronchial tree.(1) Since 
the introduction of the ﬁberoptic bronchoscope by Shigeto Ikeda,(2) 
bronchoscopy has revolutionized the practice of pulmonary medicine. 
In lung cancer, due to advances in real-time imaging and catheter based 
techniques, bronchoscopy remains pivotal not only in diagnosis and 
staging but also allows therapeutic intervention for airway restoration 
in patients with central airway obstruction and treatment of early cen-
tral airway cancers. Flexible bronchoscopy has supplanted rigid bron-
choscopy as the preferred procedure except for better airway control in 
massive hemoptysis and deployment of certain stents. Since bronchos-
copy allows access to the lung, it is a tool that enables researchers to 
better understand lung carcinogenesis, to prognosticate by means of 
biomarkers as well as in monitoring tumor response to targeted therapy 
by in-vivo microdynamic imaging.(3-5) 
Diagnosis 
In patients suspected with lung cancer, integrated positron emission to-
mography (PET)/CT assists the bronchoscopist in the optimal selection 
of techniques to facilitate diagnosis and staging. Bronchial washing, 
brushing, endobronchial and transbronchial biopsy have variable yields 
depending on tumor location and accessibility.(6) The addition of 
needle aspiration for endobronchial, submucosal, peripheral pulmo-
nary lesion or peribronchial lymph node not only increases diagnostic 
yield, it is highly cost-effective by obviating further need for invasive 
interventions.(7;8) 
Multi-detector helical CT(9) that allows reformatting of axial images 
into 3-dimensional virtual bronchoscopy has led to more precise target-
ing of peripheral pulmonary nodules for biopsy via electromagnetic 
steering probe or ultrathin bronchoscope.(10-12) The sensor probe is 
guided towards the target, and tissue sampling performed with forceps, 
needle or curette via guide sheath or direct bronchoscopic visualiza-
tion.(11;12) Seemingly attractive, navigational bronchoscopy is not 
